Icosavax shares positive data for RSV-hMPV vaccine, sets up $67.8M direct stock offering

Seattle-based Icosavax may have failed in its attempt at a Covid-19 vaccine in 2022 but it released early data on its bivalent vaccine candidate for RSV and human metapneumovirus (hMPV) – and announced a $67.8 million direct offering of its common stock yesterday. The vaccine candidate for older adults, dubbed…

Click here to view original post